Mantuano, P.; Boccanegra, B.; Conte, E.; De Bellis, M.; Cirmi, S.; Sanarica, F.; Cappellari, O.; Arduino, I.; Cutrignelli, A.; Lopedota, A.A.;
et al. β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation. Biomolecules 2021, 11, 1742.
https://doi.org/10.3390/biom11111742
AMA Style
Mantuano P, Boccanegra B, Conte E, De Bellis M, Cirmi S, Sanarica F, Cappellari O, Arduino I, Cutrignelli A, Lopedota AA,
et al. β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation. Biomolecules. 2021; 11(11):1742.
https://doi.org/10.3390/biom11111742
Chicago/Turabian Style
Mantuano, Paola, Brigida Boccanegra, Elena Conte, Michela De Bellis, Santa Cirmi, Francesca Sanarica, Ornella Cappellari, Ilaria Arduino, Annalisa Cutrignelli, Angela Assunta Lopedota,
and et al. 2021. "β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation" Biomolecules 11, no. 11: 1742.
https://doi.org/10.3390/biom11111742
APA Style
Mantuano, P., Boccanegra, B., Conte, E., De Bellis, M., Cirmi, S., Sanarica, F., Cappellari, O., Arduino, I., Cutrignelli, A., Lopedota, A. A., Mele, A., Denora, N., & De Luca, A.
(2021). β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation. Biomolecules, 11(11), 1742.
https://doi.org/10.3390/biom11111742
